H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report)’s stock price traded down 0% during trading on Monday . The stock traded as low as $22.00 and last traded at $22.00. 7,500 shares were traded during trading, an increase of 327% from the average session volume of 1,758 shares. The stock had previously closed at $22.01.
Analyst Upgrades and Downgrades
A number of analysts have commented on HLUYY shares. Barclays downgraded H. Lundbeck A/S from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, November 14th. Morgan Stanley assumed coverage on H. Lundbeck A/S in a research report on Tuesday, November 14th. They issued an “underweight” rating on the stock.
H. Lundbeck A/S Stock Performance
H. Lundbeck A/S Company Profile
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.
- Five stocks we like better than H. Lundbeck A/S
- What is a Mid Cap Stock? How to Invest
- 3 attractive stocks that insiders are buying
- Stock Splits, Do They Really Impact Investors?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Investors Need to Know to Beat the Market
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.